Cargando…
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma
OBJECTIVE: Ovarian cancer is one of the leading causes of cancer deaths in women. Ovarian cancer is diagnosed at the late stages and generally relapses within 12-14 months of cytoreductive surgery. This is attributed to lack of precise molecular detection methodologies to detect and track the diseas...
Autores principales: | S, Sandeep Kumar, Swamy, Shalini N, Premalatha, C S, Pallavi, V R, Gawari, Ramesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982682/ https://www.ncbi.nlm.nih.gov/pubmed/31653147 http://dx.doi.org/10.31557/APJCP.2019.20.10.3001 |
Ejemplares similares
-
Metabolic Reprogramming and Lipophagy Mediates Survival of Ascites Derived Metastatic Ovarian Cancer Cells
por: S, Sandeep Kumar, et al.
Publicado: (2022) -
Aberrant Promoter Hypermethylation of RASSF Family Members in Merkel Cell Carcinoma
por: Richter, Antje M., et al.
Publicado: (2013) -
Circulating Hypermethylated RASSF1A as a Molecular Biomarker for Diagnosis of Hepatocellular Carcinoma
por: Mansour, Lamiaa A, et al.
Publicado: (2017) -
Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma
por: van Zogchel, Lieke M. J., et al.
Publicado: (2020) -
Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma
por: Lázcoz, Paula, et al.
Publicado: (2006)